Wang Jing, Xue Haojie, He Jinyu, Deng Li, Tian Julong, Jiang Yang, Feng Jian
Department of Cardiology, Stem Cell Immunity and Regeneration Key Laboratory of Luzhou, The Affiliated Hospital of Southwest Medical University; Southwest Medical University Affiliated Hospital Medical Group Gulin Hospital (Gulin County People's Hospital), Luzhou, Sichuan, China.
Department of Rheumatology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China.
Diabetol Metab Syndr. 2024 Sep 18;16(1):232. doi: 10.1186/s13098-024-01466-x.
Diabetic cardiomyopathy (DCM) is a kind of myocardial disease that occurs in diabetes patients and cannot be explained by hypertensive heart disease, coronary atherosclerotic heart disease and other heart diseases. Its pathogenesis may be closely related to programmed cell death, oxidative stress, intestinal microbes and micro-RNAs. The excessive activation of mineralocorticoid receptors (MR) in DCM can cause damage to the heart and kidneys. The third-generation non-steroidal mineralocorticoid receptor antagonist (MRA), finerenone, can effectively block MR, thus playing a role in protecting the heart and kidneys. This review mainly introduces the classification of MRA, and the mechanism of action, applications and limitations of finerenone in DCM, in order to provide reference for the study of treatment plans for DCM patients.
糖尿病性心肌病（DCM）是一种发生在糖尿病患者中的心肌疾病，不能用高血压性心脏病、冠状动脉粥样硬化性心脏病等其他心脏病来解释。其发病机制可能与程序性细胞死亡、氧化应激、肠道微生物和微小RNA密切相关。DCM中盐皮质激素受体（MR）的过度激活可导致心脏和肾脏损伤。第三代非甾体类盐皮质激素受体拮抗剂（MRA）非奈利酮可有效阻断MR，从而发挥心脏和肾脏保护作用。本综述主要介绍MRA的分类，以及非奈利酮在DCM中的作用机制、应用和局限性，以便为DCM患者治疗方案的研究提供参考。
